Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics.
Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their prognosis remains poor. This analysis was conducted to determine the clinical activity of lenalidomide in patients with high-risk disease. Relapsed/refractory patients with CLL enrolled in a phase II clinical trial who had del(11q)(q22.3) or del(17p)(p13.1) were included in this analysis. Patients received single agent lenalidomide for 21 days of the 4 week treatment cycle. The overall response rate among patients with high-risk cytogenetics was 38%, with 19% of patients achieving a complete response. Median progression-free survival was 12.1 months, which is higher than demonstrated with other agents in comparable patient populations. In addition, the estimated 2-year survival probability was 58%, demonstrating that the responses achieved with lenalidomide are durable, even in patients with CLL with high-risk disease with poor risk cytogenetics.
Sher
Taimur
T
Department of Medicine, Roswell Park Cancer Institute, NY 14263, USA.
Miller
Kena C
KC
Lawrence
David
D
Whitworth
Amy
A
Hernandez-Ilizaliturri
Francisco
F
Czuczman
Myron S
MS
Miller
Austin
A
Lawrence
William
W
Bilgrami
Syed Ali
SA
Sood
Raman
R
Wood
Margaret T
MT
Block
Annemarie W
AW
Lee
Kelvin
K
Chanan-Khan
Asher Alban
AA
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002872:Chromosome Deletion; D002880:Chromosomes, Human, Pair 11; D002886:Chromosomes, Human, Pair 17; D003582:Cytogenetics; D018572:Disease-Free Survival; D006801:Humans; D000077269:Lenalidomide; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000235:genetics*; D008875:Middle Aged; D011379:Prognosis; D012008:Recurrence; D012306:Risk; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide